Understanding the impact of immune-mediated selection on lung cancer evolution
Open Access
- 24 February 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 124 (10), 1615-1617
- https://doi.org/10.1038/s41416-020-01232-6
Abstract
Understanding how a tumour evolves and avoids immune recognition is paramount to improving cancer immunotherapy and patient outcome. Here we examine our recent integration of multi-region genomic, transcriptomic, epigenomic, pathology, and clinical data, highlight the need for a systematic examination of immune escape mechanisms, and discuss implications for immunotherapy approaches.Keywords
This publication has 15 references indexed in Scilit:
- Epigenetic modifiers as new immunomodulatory therapies in solid tumoursAnnals of Oncology, 2018
- Allele-Specific HLA Loss and Immune Escape in Lung Cancer EvolutionCell, 2017
- Cancer Evolution Constrained by the Immune MicroenvironmentCell, 2017
- Tracking the Evolution of Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung CancerCancer Discovery, 2017
- The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue ArchitectureVaccines, 2017
- T-Cell Transfer Therapy Targeting Mutant KRAS in CancerThe New England Journal of Medicine, 2016
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeditingNature, 2012
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- Mechanisms of Immune Evasion by TumorsAdvances in Immunology, 2006